Literature DB >> 11329213

Late stent thrombosis in the absence of prior intracoronary brachytherapy.

L I Heller1, K C Shemwell, K Hug.   

Abstract

Late stent thrombosis has not been reported in the absence of prior coronary brachytherapy. We reviewed our experience in 1,855 consecutive patients who received at least one stent and did not receive coronary brachytherapy. Half of all stent thromboses occurred within the first week and nearly 65% (22) occurred within 15 days. The incidence of stent thrombosis within this traditional time frame was 1.2%. An additional 12 patients, however, presented with stent thrombosis between 33 and 270 days post-procedure (mean = 72.9 +/- 23 days). The true incidence of stent thrombosis was therefore 1.8% (34/1,855). There were three bypass operations, one stroke and two deaths in the late stent thrombosis group. Late stent thrombosis is an unusual but serious complication in patients who have not received coronary brachytherapy. Intracoronary radiation may potentiate a phenomenon that already occurs after stent deployment. Prolonged treatment (6-12 months) with anti-platelet agents should be considered after percutaneous intervention with coronary stents. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11329213     DOI: 10.1002/ccd.1124

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

1.  The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents.

Authors:  Machael P Love; Erick Schampaert; Eric A Cohen; John G Webb; Todd J Anderson; Marino Labinaz; Jean-François Tanguay; Vladimír Dzavík
Journal:  Can J Cardiol       Date:  2007-02       Impact factor: 5.223

2.  Late adverse events after drug-eluting stent implantation.

Authors:  David F Kong; Eric L Eisenstein; Robert Harrington
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

Review 3.  Drug-eluting stents: insights into safety and indications.

Authors:  Walid Hassan
Journal:  Ann Saudi Med       Date:  2008 Mar-Apr       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.